NEW YORK, NY / ACCESSWIRE / July 15, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the lead plaintiff deadlines listed below to petition the court, and those interested in their eligibility are encouraged to contact the firm. There will be no cost or obligation to you.
Lyft, Inc. (LYFT)
Lawsuit on behalf of: investors who purchased pursuant or traceable to the Company's Offering and Registration Statement issued in relation to the March 28, 2019 IPO
Lead Plaintiff Deadline : July 16, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/lyft-inc-loss-form?prid=2412&wire=1
According to the lawsuit, Lyft’s Offering materials issued in connection with its IPO failed to disclose that: (1) Lyft’s claimed ridesharing position was overstated; (2) more than 1,000 of the bicycles in Lyft’s rideshare program suffered from safety issues that would lead to their recall; (3) Lyft’s drivers were becoming disincentivized from driving for Lyft; (4) Lyft failed to warn investors that a labor disruption could affect its operations; and (5) as a result, Lyft’s public statements were materially false and misleading at all relevant times.
Intersect ENT, Inc. (XENT)
Lawsuit on behalf of: investors who purchased August 1, 2018 - May 6, 2019
Lead Plaintiff Deadline : July 15, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/intersect-ent-inc-loss-form?prid=2412&wire=1
According to the filed complaint, during the class period, Intersect ENT, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Intersect lacked adequate reimbursement representatives to ensure physicians had access to SINUVA, Intersect’s sinus implant; (2) Intersect’s sales force would focus on ensuring reimbursement; (3) Intersect’s sales representatives were less focused on driving sales; (4) physicians were less likely to adopt Intersect’s SINUVA due to transaction costs associated with seeking reimbursement; (5) Intersect would increase staffing to address these issues; and (6) as a result of the foregoing, defendants’ positive statements about Intersect’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Ra Medical Systems, Inc. (RMED)
Lawsuit on behalf of: investors who purchased stockholders that purchased Ra Medical securities pursuant and/or traceable to the Company’s September 2018 initial public offering.
Lead Plaintiff Deadline : August 6, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/ra-medical-systems-inc-loss-form?prid=2412&wire=1
According to the filed complaint, (1) the Company’s evaluation of sales personnel candidates was inadequate; (2) the Company’s training program for sales personnel was inadequate; (3) as a result, the Company could not reasonably assure that its newly hired sales personnel were adequately experienced; (4) as a result, the Company would suffer a shortage of qualified sales personnel; (5) the Company’s manufacturing process could not reasonably support increased catheter production; (6) as a result, the Company would suffer production delays; and (7) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Fax: (212) 363-7171
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com: